Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk

American Heart Journal

Volumn 157, Issue 3, 2009, Pages 502-508

  Joyner, Campbell D ^a   Peters, Ron J G ^b   Afzal, Rizwan ^c   Chrolavicius, Susan ^c   Mehta, Shamir R ^d   Fox, Keith A A ^e   Granger, Christopher B ^f   Franzosi, Maria Grazia ^g   Flather, Marcus ^h   Budaj, Andrzej ⁱ   Bassand, Jean Pierre ^j   Yusuf, Salim ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ GROCHOWSKI HOSPITAL   (Poland)

^j UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ENOXAPARIN; HEMORRHAGE; HUMANS; POLYSACCHARIDES; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 60649089741     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.10.028     Document Type: Article

References (19)

1. Bassand J.-P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
2. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 116 (2007) 803-877
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
4. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
5. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 359 (2002) 189-198
6. Mehta S.R., Cannon C.P., Fox K.A., et al. Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
7. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-1782
8. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
9. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision-making. JAMA 284 (2000) 835-842
10. Granger C.G., Goldberg R.J., Dabbous O.H., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
11. Eagle K.A., Lim M.J., Dabbous O.H., et al., for the GRACE investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post-discharge death in an international registry. JAMA 291 (2004) 2727-2733
12. Boersma E., Pieper K.S., Steyerberg E.W., et al., for the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an International Trial of 9461 patients. Circulation 101 (2000) 2557-2567
13. Fox K.A.A., Dabbous O.H., Goldberg R.J., et al., for the GRACE Investigators. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 333 (2006) 1091-1094
14. MICHELANGELO OASIS 5 Steering Committee. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 150 (2005) 1107.e1-1107.e10
15. Moscucci M., Fox K.A.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
16. Fox K.A.A., Bassand J.P., Mehta S.R., et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes. Ann Intern Med 147 (2007) 304-310
17. Budaj A., Eikelboom J.W., Mehta S.R., et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2008) (Electronic Publication 2008, August 18)
18. Mehta R.S., Granger C.B., Eikelboom J.W., et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Am Coll Cardiol 50 (2007) 1742-1751
19. Budaj A., Yusuf S., Mehta S.R., et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106 (2002) 1622-1626